Impact of Plant-Derived Compounds on Amyotrophic Lateral Sclerosis

被引:4
|
作者
Goncalves de Oliveira, Lucas Matheus [1 ]
Carreira, Rodrigo Barreto [1 ]
Ribeiro de Oliveira, Juciele Valeria [1 ]
do Nascimento, Ravena Pereira [1 ]
dos Santos Souza, Cleide [2 ]
Trias, Emiliano [3 ]
Amaral da Silva, Victor Diogenes [1 ]
Costa, Silvia Lima [1 ]
机构
[1] Univ Fed Bahia, Inst Hlth Sci, Dept Biochem & Biophys, Lab Neurochem & Cell Biol, BR-40110100 Salvador, BA, Brazil
[2] Univ Sheffield, Sheffield Inst Translat Neurosci SITraN, Sheffield, England
[3] Inst Pasteur Montevideo, Montevideo, Uruguay
关键词
Amyotrophic lateral sclerosis; Natural compounds; Motor neurons; Glial cells; Neuroprotection; MOTOR-NEURON DEGENERATION; SUPEROXIDE-DISMUTASE SOD1; SPINAL-CORD-INJURY; MOUSE MODEL; ALZHEIMERS-DISEASE; OXIDATIVE-STRESS; ASIATIC ACID; EPIGALLOCATECHIN-GALLATE; BETA-CARYOPHYLLENE; GGGGCC REPEAT;
D O I
10.1007/s12640-022-00632-1
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Amyotrophic lateral sclerosis (ALS) is a fatal illness characterized by progressive motor neuron degeneration. Conventional therapies for ALS are based on treatment of symptoms, and the disease remains incurable. Molecular mechanisms are unclear, but studies have been pointing to involvement of glia, neuroinflammation, oxidative stress, and glutamate excitotoxicity as a key factor. Nowadays, we have few treatments for this disease that only delays death, but also does not stop the neurodegenerative process. These treatments are based on glutamate blockage (riluzole), tyrosine kinase inhibition (masitinib), and antioxidant activity (edaravone). In the past few years, plant-derived compounds have been studied for neurodegenerative disorder therapies based on neuroprotection and glial cell response. In this review, we describe mechanisms of action of natural compounds associated with neuroprotective effects, and the possibilities for new therapeutic strategies in ALS.
引用
收藏
页码:288 / 309
页数:22
相关论文
共 50 条
  • [41] Amyotrophic lateral sclerosis
    Pearce, JMS
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2002, 73 (06): : 671 - 671
  • [42] Amyotrophic lateral sclerosis
    van Es, Michael A.
    Hardiman, Orla
    Chio, Adriano
    Al-Chalabi, Ammar
    Pasterkamp, R. Jeroen
    Veldink, Jan H.
    Van den Berg, Leonard H.
    LANCET, 2017, 390 (10107): : 2084 - 2098
  • [43] AMYOTROPHIC LATERAL SCLEROSIS
    Owens, Brian
    NATURE, 2017, 550 (7676) : S105 - S105
  • [44] AMYOTROPHIC LATERAL SCLEROSIS
    NORRIS, FH
    SANG, K
    DENYS, EH
    ARCHIBALD, KC
    LEBO, C
    MAYO CLINIC PROCEEDINGS, 1978, 53 (08) : 544 - 544
  • [45] AMYOTROPHIC LATERAL SCLEROSIS
    ROSSBERG, C
    MENNEL, HD
    HEENE, R
    MEDIZINISCHE WELT, 1984, 35 (03): : 87 - 91
  • [46] Amyotrophic lateral sclerosis
    Hardiman, Orla
    Al-Chalabi, Ammar
    Chio, Adriano
    Corr, Emma M.
    Logroscino, Giancarlo
    Robberecht, Wim
    Shaw, Pamela J.
    Simmons, Zachary
    van den Berg, Leonard H.
    NATURE REVIEWS DISEASE PRIMERS, 2017, 3
  • [47] AMYOTROPHIC LATERAL SCLEROSIS
    ALPERS, BJ
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1961, 176 (10): : 890 - &
  • [48] Amyotrophic lateral sclerosis
    Brian Owens
    Nature, 2017, 550 : S105 - S105
  • [49] Amyotrophic lateral sclerosis
    Collins, J
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1903, 125 : 939 - 967
  • [50] Amyotrophic lateral sclerosis
    Jackson, CE
    Bryan, WW
    SEMINARS IN NEUROLOGY, 1998, 18 (01) : 27 - 39